ReviewInternational journal of molecular sciences2013
The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.
Review in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Pooled it
- A rest-activity biomarker to predict response to SSRIs in major depressive disorder.Journal of psychiatric research · 2015Trial
- Methylphenidate ameliorates depressive comorbidity in ADHD children without any modification on differences in serum melatonin concentration between ADHD subtypes.International journal of molecular sciences · 2014Trial
- Effects of Combined Exercise Interventions on Cognition in Older Persons: A Systematic Review and Meta-Analysis.Healthcare (Basel, Switzerland) · 2026Review
- Seizures Temporally Associated With SSRI Treatment: A Two-Case Report Exploring Agomelatine as a Treatment Alternative.Case reports in psychiatry · 2026Article
- C-Reactive Protein Does Not Predict Future Depression Onset in Adolescents: Preliminary Findings from a Longitudinal Study.Journal of child and adolescent psychopharmacology · 2024Article
- The Use of Melatoninergic Antidepressants for Stabilization of Remission in Depression Comorbid with Alcohol Abuse, Anxiety or Neuropsychiatric Disorders: A Systematic Review.Consortium psychiatricum · 2024Review
- Moderating effect of sleep quality in the relationship between coping and distress among medical students.Frontiers in psychiatry · 2024Article
- Psychological dominant stressor modification to an animal model of depression with chronic unpredictable mild stress.Veterinary world · 2023Article
- Melatonergic Receptors (Mt1/Mt2) as a Potential Additional Target of Novel Drugs for Depression.Neurochemical research · 2022Review
- Sedative-Hypnotic Activity of the Water Extracts ofClocks & sleep · 2022Article
- Article
- New agents and perspectives in the pharmacological treatment of major depressive disorder.Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- Agomelatine, A Potential Multi-Target Treatment Alternative for Insomnia, Depression, and Osteoporosis in Postmenopausal Women: A Hypothetical Model.Frontiers in psychiatry · 2021Article
- Molecular Regulation of the Melatonin Biosynthesis Pathway in Unipolar and Bipolar Depression.Frontiers in pharmacology · 2021Article
- Melatonin and Depression: A Translational Perspective From Animal Models to Clinical Studies.Frontiers in psychiatry · 2021Review
- Correlates of C-reactive protein with neural reward circuitry in adolescents with psychiatric symptoms.Brain, behavior, & immunity - health · 2020Article
- Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations.Depression and anxiety · 2020Review
- Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables.Psychiatry investigation · 2020Article
- Treating Circadian Rhythm Disruption in Bipolar Disorder.Current psychiatry reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melatonin exerts its actions through membrane MT1/MT2 melatonin receptors, which belong to the super family of G-protein-coupled receptors consisting of the typical seven transmembrane domains. MT1 and MT2 receptors are expressed in various tissues of the body either as single ones or together. A growing literature suggests that the melatonergic system may be involved in the pathophysiology of mood and anxiety disorders. In fact, some core symptoms of depression show disturbance of the circadian rhythm in their clinical expression, such as diurnal mood and other symptomatic variation, or are closely linked to circadian system functioning, such as sleep-wake cycle alterations. In addition, alterations have been described in the circadian rhythms of several biological markers in depressed patients. Therefore, there is interest in developing antidepressants that have a chronobiotic effect (i.e., treatment of circadian rhythm disorders). As melatonin produces chronobiotic effects, efforts have been aimed at developing agomelatine, an antidepressant with melatonin agonist activity. The present paper reviews the role of the melatonergic system in the pathophysiology of mood and anxiety disorders and the clinical characteristics of agomelatine. Implications of agomelatine in "real world" clinical practice will be also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.